-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group has been ranked among the Top 100 Chinese Chemical Pharmaceutical Companies for 2023, coming in at No. 34—five places higher than the previous year.
Category:
发布时间：2024-06-25
【概要描述】
Bathed in the misty rain, South Taihu Lake resembles a traditional ink-and-wash painting—ethereal, vibrant, and ever-changing—as it warmly welcomes guests from near and far. On June 25, the highly anticipated 2024 Misi Conference (China Pharmaceutical and Health Industry Symbiosis Conference), which has drawn intense attention from China’s pharmaceutical industry, officially opened in Huzhou, Zhejiang Province.
Bathed in the misty rain, the southern waters of Taihu Lake resemble a traditional ink-and-wash painting—ethereal, vibrant, and ever-changing—as it welcomes guests from near and far. On June 25, the highly anticipated 2024 Misi Conference (China Pharmaceutical and Health Industry Symbiosis Conference), which has drawn significant attention from China’s pharmaceutical industry, kicked off in Huzhou, Zhejiang Province.
The 2024 MiSi Conference is hosted by MiNeiNet, a leading pharmaceutical information service platform in the industry. With the theme “Resilience and Progress: Ushering in a New Era,” the conference brings together domestic industry experts, scholars, and business leaders to jointly explore new challenges in the context of high-quality development and to recognize emerging benchmarks for industrial advancement in the new era.
On the evening of June 25, at the Misi Star Awards Ceremony, the Misi Conference Organizing Committee unveiled the highly anticipated “2023 Top 100 Chinese Pharmaceutical Companies” series of rankings. Thanks to its outstanding innovation capabilities, robust product quality, and steady market influence, the Group was honored on the sub-ranking “2023 Top 100 Chinese Chemical Pharmaceutical Enterprises,” securing the 34th position—five places higher than the previous year.
In recent years, the Group has proactively built an innovative, high-value ecosystem, focusing on key therapeutic areas such as anti-infectives, respiratory diseases, neurological disorders, cardiovascular and cerebrovascular conditions, gastroenterology, anesthesia, endocrinology, oncology, and dialysis. It has steadily advanced integrated development of active pharmaceutical ingredients (APIs) and finished dosage forms, accelerated R&D on high-end complex generic drugs, innovative medicines, specialty APIs, pharmaceutical packaging materials, and products undergoing bioequivalence evaluation, and achieved synchronized progress across the entire drug development–market translation value chain. As a result, the Group has established a uniquely differentiated product portfolio and gained new competitive advantages in the industry. In 2023, driven by continuous product innovation and sustained accumulation, the Group secured approval for 88 new products, ranking among the top in the industry in terms of both submissions and approvals. This robust innovation has effectively supported the ongoing optimization of the company’s supply structure, enhanced the quality and efficiency of scale-up, and propelled a significant leap in its industry influence and competitiveness.
According to reports, this year’s ranking focuses on assessing pharmaceutical companies’ innovation-driven capabilities and professional marketing strength, with the final results determined through quantitative analysis based on exclusive end-market data from Mene.net. The Top 100 Chinese Pharmaceutical Companies list is one of the most widely recognized brand rankings in the domestic pharmaceutical industry, with the companies included representing leading competitiveness, influence, and development levels within the sector.
As a renowned annual event in the pharmaceutical and healthcare industry, the Misi Conference is defined by four core pillars—strategic foresight, professional empowerment, data-driven insights, and brand connectivity. It brings together more than 5,000 industry leaders from diverse stakeholder groups, including government and association leaders, clinical experts, industry specialists, China’s Top 100 pharmacy chains, the top 20 provincial-level chain operators, the Top 100 pharmaceutical manufacturers, hospital- and community-based retail outlets, leading innovative pharmaceutical companies and technology platforms, CXO firms, pharmaceutical industrial parks, members of the MiNei Network, board members of the MiFang Association, affiliates of the CPMC Pharmacy Management Academy, and mainstream media both within and outside the industry. These distinguished representatives share specialized knowledge, explore innovative development models, facilitate resource alignment and collaboration across the entire value chain, and drive continuous industry upgrading and transformation.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091